Aptevo Therapeutics and Niowave, Inc. have announced the establishment of a 50/50 partnership aimed at the development of innovative cancer therapies. This collaboration is expected to leverage the strengths of both companies in order to advance the research and commercialization of new cancer drugs. The partnership reflects a commitment to addressing unmet medical needs in oncology through combined expertise and resources. Further details regarding the specific projects and timelines associated with this partnership have yet to be disclosed.
Related Articles
Don't miss out on breaking stories and in-depth articles.